Olmesartan Medoxomilo + Hidroclorotiazida Blixie (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Blixie, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is intended for adult patients. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Blixie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Blixie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin‑aldosterone system and promoting diuresis.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Resistant hypertension: provides additional blood‑pressure control when monotherapy is insufficient. - Hypertension with fluid retention: combines ARB action with a thiazide diuretic to reduce volume overload.

Olmesartan medoxil with hydrochlorothiazide may cause a range of adverse reactions.

Common Side Effects: - Dizziness: light‑headed sensation, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated potassium levels that may affect heart rhythm. - Allergic reactions: rash, itching, or swelling of the face and throat. - Liver enzyme elevation: abnormal liver function test results.

When prescribing Olmesartan Medoxil + Hydrochlorothiazide, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium before initiation and during therapy. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Volume depletion: ensure patient is not dehydrated before starting therapy. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil + Hydrochlorothiazide can interact with several medicines, requiring clinical awareness.

Major Interactions (Avoid): - Aliskiren: combined use may cause excessive potassium loss and renal impairment. - Lithium: risk of lithium toxicity due to reduced renal clearance. - NSAIDs: may blunt antihypertensive effect and increase risk of kidney injury.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics: may cause elevated potassium levels. - Antidiabetic drugs: may enhance hypoglycaemic effect, requiring dose adjustment.